Inside Look at Sola...
Health Care: Drugs
Poniard Pharmaceuticals Inc. (PARD: NASDAQ)
$2.95 0.28 | 10.49%
12/21/11 - 03:57 PM ET
7.71K / 15.80K
Vol / Avg. Vol:2.54 / 2.67
Open / Prev. Close:2.54 - 2.95
Today's Range:2.55 - 30.00
52 Wk Range:-47.42%
Performance YTD:TheStreet Rating:
Portfolios with PARD
- Portfolio NameUser Type
- Contributor5 Health Care Stocks With U...
- UserLegal Tender
- UserASCO 2010 Part 2
- UserThe 1000 Club
- Userabk
- Userwishing & hoping
- UserTachyon1
- Userrusi
- Userweezer
- UserAlina
Latest PARD Headlines from TheStreet
- 5 Health Care Stocks With Upside 03.21.11 | 11:03 am
- Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.09.10 | 07:11 pm
- Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.09.10 | 06:08 pm
- Stocks Under $5 With the Most Sell Ratings 06.24.10 | 07:06 am
- Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 05.10.10 | 08:05 pm
- Poniard, Xfone: Early Volume Plays 03.24.10 | 09:03 am
- Cell Therapeutics, Zoom Technologies: Midday Volume Plays 03.08.10 | 11:03 am
- Medivation: Biotech Stock Mailbag 03.03.10 | 11:03 am
- Antigenics Files $100 Million Mixed Shelf: BioBuzz 01.25.10 | 12:01 pm
- New Gold, Poniard: Early Volume Plays 01.25.10 | 07:01 am
Press Releases for PARD
- The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Of Poniard Pharmaceuticals, Inc. - Business Wire 07.07.11 | 07:07 pm
- Law Office Of Brodsky & Smith, LLC Announces Investigation Of Poniard Pharmaceuticals, Inc. - Business Wire 06.22.11 | 07:06 pm
- Poniard Pharmaceuticals Completes Voluntary Prepayment Of Term Loans And Secures New Committed Equity Financing Facility - PR Newswire 12.21.10 | 06:12 am
- Poniard Pharmaceuticals Announces Plan For Voluntary Prepayment Of Term Loan And Transfer To Nasdaq Capital Market - PR Newswire 12.16.10 | 08:12 am
- Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program - PR Newswire 11.04.10 | 08:11 am
- Poniard Pharmaceuticals To Host Third Quarter 2010 Financial Results Conference Call - PR Newswire 11.03.10 | 08:11 am
- Poniard Pharmaceuticals To Host Second Quarter 2010 Financial Results Conference Call - PR Newswire 08.02.10 | 08:08 am
- Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related To Minimum Bid Price - PR Newswire 07.22.10 | 04:07 pm
- Poniard Announces Final Data From Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer - PR Newswire 06.05.10 | 04:06 pm
- Poniard Pharmaceuticals To Host First Quarter 2010 Financial Results Conference Call On May 10 - PR Newswire 05.03.10 | 08:05 am
Partner Headlines for PARD
- Microcap Movers For Friday November 18, 2011 - Benzinga 11.19.11 | 03:11 pm
- UPDATE: Poniard Pharmaceuticals Resumes Trading; Up Over 35% - Benzinga 06.22.11 | 04:06 pm
- Poniard Pharma Beats EPS By $0.02 (PARD) - Benzinga 03.30.11 | 04:03 pm
- Poniard Pharmaceuticals Reports Q4 EPS $(0.11) - Benzinga 03.30.11 | 04:03 pm
- China Biotech in Review: Thermo Fisher Scientific Displays Increased Commitment - Seeking Alpha 03.06.11 | 08:03 am
- 24 Stocks and ETFs With Very High Put / Call Ratios - Seeking Alpha 08.05.10 | 09:08 am
- UPDATE 2-Poniard says resuming regulatory efforts on key drug - Reuters 05.10.10 | 05:05 pm
- UPDATE 3-Poniard suspends regulatory efforts on key drug - Reuters 03.24.10 | 12:03 pm
